{"entity":{"id":"nct04674683","kind":"trial","name":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","aka":[],"tldr":"A phase 3 trial of Nivolumab in melanoma, run by HUYABIO International, LLC., active and no longer recruiting.","summary":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma is a phase 3 interventional study registered as NCT04674683 by HUYABIO International, LLC., with 450 participants enrolled, started 2021-08-12 and due to reach its primary completion in 2026-07. Interventions recorded: HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab. Conditions listed: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04674683","url":"https://clinicaltrials.gov/study/NCT04674683"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":["huyabio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04674683","phase":"3","setting":"A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors","sponsor":"HUYABIO International, LLC.","enrolled":450,"outcomes":[]},"route":"/trials/nct04674683/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/"}]}}